BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
BioLineRx (NASDAQ: BLRX) will release unaudited third quarter results for the period ended September 30, 2025 on Monday, November 24, 2025 before U.S. markets open.
Management will host a conference call on November 24, 2025 at 8:30 a.m. EST with remarks by Philip Serlin, CEO. U.S. dial-in is +1-888-281-1167; international dial-in is +972-3-918-0685. A live webcast and replay will be available on the company website; the replay will be posted about two hours after the call and a dial-in replay runs until November 26, 2025 (+1-888-295-2634 U.S., +972-3-925-5904 international).
BioLineRx (NASDAQ: BLRX) comunicherà i risultati trimestrali non riesaminati del terzo trimestre per il periodo terminato 30 settembre 2025 il lunedì 24 novembre 2025 prima dell'apertura dei mercati statunitensi.
La direzione terrà una conference call il 24 novembre 2025 alle ore 8:30 EST con interventi di Philip Serlin, CEO. Il numero statunitense è +1-888-281-1167; il numero internazionale è +972-3-918-0685. Una presentazione in streaming e la riproduzione saranno disponibili sul sito dell'azienda; la riproduzione sarà pubblicata circa due ore dopo la chiamata e una riproduzione telefonica è disponibile fino al 26 novembre 2025 (+1-888-295-2634 USA, +972-3-925-5904 internazionale).
BioLineRx (NASDAQ: BLRX) publicará resultados no auditados del tercer trimestre para el periodo que terminó el 30 de septiembre de 2025 el lunes 24 de noviembre de 2025 antes de la apertura de los mercados de EE. UU.
La dirección organizará una conferencia telefónica el 24 de noviembre de 2025 a las 8:30 a. m. EST con comentarios de Philip Serlin, CEO. El número de EE. UU. para marcar es +1-888-281-1167; el de marcado internacional es +972-3-918-0685. Se podrá ver una transmisión en vivo y una repetición en la página web de la empresa; la repetición estará disponible aproximadamente dos horas después de la llamada y una reproducción telefónica estará disponible hasta el 26 de noviembre de 2025 (+1-888-295-2634 EE. UU., +972-3-925-5904 internacional).
BioLineRx (NASDAQ: BLRX)는 2025년 9월 30일에 종료되는 기간의 제3분기에 대한 미감사 결과를 2025년 11월 24일 월요일 미국 시장 개장 전에 발표합니다.
경영진은 2025년 11월 24일 8:30 a.m. EST에 Philip Serlin, CEO의 발언과 함께 컨퍼런스 콜을 진행합니다. 미국 내 다이얼인은 +1-888-281-1167; 국제 다이얼인은 +972-3-918-0685입니다. 생중계 및 재연은 회사 웹사이트에서 이용 가능하며, 재연은 콜 종료 후 약 두 시간 내에 게시되고 다이얼인 재연은 2025년 11월 26일까지 제공됩니다 (+1-888-295-2634 미국, +972-3-925-5904 국제).
BioLineRx (NASDAQ: BLRX) publiera les résultats non vérifiés du troisième trimestre pour la période se terminant le 30 septembre 2025 le lundi 24 novembre 2025 avant l'ouverture des marchés américains.
La direction animera une conférence téléphonique le 24 novembre 2025 à 8h30 EST avec des remarques de Philip Serlin, PDG. Le numéro d'appel des États-Unis est +1-888-281-1167; l'appel international est +972-3-918-0685. Une retransmission en direct et une rediffusion seront disponibles sur le site de l'entreprise; la rediffusion sera publiée environ deux heures après l'appel et une rediffusion téléphonique sera disponible jusqu'au 26 novembre 2025 (+1-888-295-2634 États-Unis, +972-3-925-5904 international).
BioLineRx (NASDAQ: BLRX) wird die ungeprüften Ergebnisse des dritten Quartals für den Zeitraum, der am 30. September 2025 endet, am Montag, den 24. November 2025 vor der Öffnung der US-Märkte veröffentlichen.
Die Geschäftsführung wird am 24. November 2025 um 8:30 Uhr EST eine Telefonkonferenz mit Anmerkungen von Philip Serlin, CEO abhalten. Die US-Wahl ist +1-888-281-1167; die internationale Wahl ist +972-3-918-0685. Eine Live-Übertragung und eine Aufzeichnung werden auf der Unternehmenswebsite verfügbar sein; die Aufzeichnung wird etwa zwei Stunden nach dem Anruf veröffentlicht, und eine telefonische Wiedergabe ist bis zum 26. November 2025 verfügbar (+1-888-295-2634 USA, +972-3-925-5904 international).
BioLineRx (NASDAQ: BLRX) ستصدر نتائج الربع الثالث غير المدققة للفترة المنتهية في 30 سبتمبر 2025 في الاثنين 24 نوفمبر 2025 قبل افتتاح الأسواق الأمريكية.
ستعقد الإدارة مكالمة مؤتمريّة في 24 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة مع ملاحظات من Philip Serlin، الرئيس التنفيذي. الرقم المحلي في الولايات المتحدة هو +1-888-281-1167؛ الرقم الدولي هو +972-3-918-0685. ستتوفر بث حي وإعادة بث على موقع الشركة الإلكتروني؛ وسيتم وضع الإعادة نحو ساعتين بعد المكالمة وتتوفر إعادة اتصال حتى 26 نوفمبر 2025 (+1-888-295-2634 الولايات المتحدة، +972-3-925-5904 دولياً).
- None.
- None.
Management to Hold Conference Call at 8:30 a.m. EST
The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-281-1167 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the
In addition, BioLineRx has established a joint venture with Hemispherian AS to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial is planned to be initiated in the first quarter of 2026.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2025-results-on-november-24-2025-302618423.html
SOURCE BioLineRx Ltd.
FAQ
When will BioLineRx (BLRX) report Q3 2025 results?
What time is the BioLineRx (BLRX) Q3 2025 conference call and who will speak?
How can investors access the BioLineRx (BLRX) November 24, 2025 webcast and replay?
What dial-in numbers should U.S. and international listeners use for the BLRX call?
How long will the phone replay of the BioLineRx (BLRX) call be available?
